Low-Dose Enzalutamide in Late-Elderly Patients (≥ 75 Years Old) Presenting With Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Low-Dose Enzalutamide in Late-Elderly Patients (≥ 75 Years Old) Presenting With Metastatic Castration-Resistant Prostate Cancer

Published:2020-12 Issue:6 Volume:18 Page:e660-e668
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Vinh-Hung Vincent^ORCID,Natchagande Gilles,Joachim Clarisse,Gorobets Olena,Drame Moustapha,Bougas Stefanos,Folefac Edmund,Nguyen Nam P.,Verschraegen Claire,Yin Ming

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference38 articles.

1. Development of a second-generation antiandrogen for treatment of advanced prostate cancer;Tran;Science,2009

2. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study;Scher;Lancet,2010

3. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

4. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

5. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study;Shore;Lancet Oncol,2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes in studies regarding older patients with prostate cancer: A systematic review;Journal of Geriatric Oncology;2024-06

2. Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report;Case Reports in Oncology;2024-04-04

3. The Lancet Commission on prostate cancer: planning for the surge in cases;The Lancet;2024-04

4. A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer;European Urology Oncology;2024-03

5. Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review;BMJ Oncology;2024-02